Longport Extends Pressure Ulcer Prevention Sales into Rehabilitation and Acute Care

  
    
  
  
    
      Longport, Inc. (OTC PK: LPTI), a medical technology specialist in 
      high-frequency high resolution ultrasound imaging, today announced that 
      it had made sales of its EPISCAN system into the transitional care / 
      rehabilitation and the acute hospital sectors for pressure ulcer 
      prevention and wound assessment. Longport’s 
      EPISCAN system has the capability to detect deep tissue injury at the 
      time of a patient’s admission to the hospital 
      which helps to determine where a pressure ulcer originates.
    
    
      The sale into the acute hospital sector was stimulated by the CMS rule 
      change described in Longport’s announcement 
      dated September 20, 2007 and entitled “CMS to 
      Stop Reimbursement for Hospital Acquired Pressure Ulcers”. 
      This CMS rule change has been widely reported in the media and is 
      expected to benefit Longport’s efforts in 
      getting the Company’s EPISCAN I-200 ultrasound 
      scanner accepted in hospitals for use in pressure ulcer prevention. The 
      images the scanner generates help facilities see the early stages of 
      deep tissue injury and thus initiate targeted preventative intervention 
      earlier, which can frequently prevent pressure ulcers developing.
    
    
      In 2008, Longport has also sold EPISCAN systems to a wound care provider 
      as well making continued sales into long term care for pressure ulcer 
      prevention.
    
    
      Paul Wilson, President of Longport commented, “Longport 
      is pleased to report the increased sales activities from a range of 
      customer groups associated with pressure ulcer prevention and wound 
      assessment. These sales reflect a significant increase in inquiries 
      received and quotations issued during the last four months from 
      prospective customers looking for new technology to document, prevent, 
      and assess pressure ulcers, as well as to reduce their potential 
      liability to sanctions and litigation.”
    
    
      About Longport, Inc.
    
    
      Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology 
      company that specializes in high resolution ultrasound imaging. After 
      several years and a multi-million dollar investment in the technology, 
      Longport has secured patents, copyrights and FDA permission to market. 
      The Company’s technology has been used to 
      engineer a unique high resolution ultrasound imaging system. For further 
      information please contact Longport, Inc. at 1-800-289-6863 or visit our 
      website at www.longportinc.com.
    
    
      Forward-looking Information and the Private Securities Litigation 
      Reform Act of 1995
    
    
      Certain statements in this press release, including statements 
      concerning product development milestones and anticipated events, are “forward-looking 
      statements” within the Private Litigation 
      Reform Act of 1995. Forward Looking Statements are based on the 
      opinions and estimates of management at the time the statements are made 
      and are subject to certain risks and uncertainties that could cause 
      actual results to differ materially from those anticipated in the 
      forward-looking statements. The words “believe,” 
      “expect,” “intend,” 
      “anticipate,” 
      variations of such words, and similar expressions identify 
      forward-looking statements, but their absence does not mean that the 
      statement is not forward-looking. These statements are not 
      guarantees of future performance and are subject to certain risks, 
      uncertainties and assumptions that are difficult to predict. Factors 
      that could affect Longport’s actual results 
      include, among others, uncertainties as to the Company’s 
      ability to manage potential problems, delays or anticipated expenses, 
      including problems, delays or expenses involving manufacturing. Readers 
      are cautioned not to place undue reliance upon these forward-looking 
      statements that speak only to the date of this release. Reference 
      is made to Longport’s 2004 annual report on 
      Form 10-K filed with the Securities and Exchange Commission for a more 
      definitive description of such factors. Longport, Inc. undertakes 
      no obligation to update publicly any forward-looking statements to 
      reflect new information, events or circumstances after the date of this 
      release or to reflect the occurrence of unanticipated events.